POLY-PRED
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPS
Approved
May 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLY-PRED is a small-molecule ophthalmic suspension approved in 1963 for inflammatory and allergic eye conditions. Delivered as eye drops, it provides topical anti-inflammatory activity directly to ocular tissues. The product represents a mature, established therapy in the ophthalmology space.
LOE Approaching
Declining phase with moderate competitive pressure (30/100) signals smaller team size and defensive rather than growth-focused commercial strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on POLY-PRED offers experience in managing a mature, stable ophthalmic franchise within a large pharmaceutical company (AbbVie), with emphasis on lifecycle management, competitive positioning, and regulatory compliance. Career progression will depend on ability to defend market share and explore lifecycle extension opportunities before generic erosion accelerates.
Brand Manager
Worked on POLY-PRED at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.